Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday. Verve is developing ...

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, sending ...

Lilly confirmed it would buy a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.

The IPO comes just a few weeks after Caris raised $168 million in a private financing round that took the total raised by the ...

Novo Nordisk, the maker of Ozempic and Wegovy, is predicted to lose billions in profits due to a minor billing error in ...

The news these days is distracting even for Wall Street's best, like Alger Funds' star stock picker and portfolio manager Patrick Kelly, who kept watch on Iran-Israel headlines while sharing secrets ...

U.S. stock index futures declined amid the ongoing Israel-Iran conflict, affecting global markets. Investor focus remains on ...

RBL LLC, a pioneering biotech venture creation studio dedicated to rapidly building companies based on breakthrough medical ...

Solar stocks crushed as Senate budget bill proposal keeps cuts to solar incentives. OpenAI secures $200 million Pentagon ...